Trial Profile
Effects of Exemestane and COX-2 inhibition on oestrogen receptor positive ductal carcinoma in situ.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Exemestane (Primary)
- Indications Ductal carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms ERISAC
- 23 Feb 2010 Clinical cancer research: an official journal of the American Association for Cancer Research.
- 17 Apr 2009 New trial record